SHREE GANESH REMEDIES LTD (SGRL) financials

SHREE GANESH REMEDIES LTD (SGRL) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.[1][2]

  • Market Cap: ₹781Cr.
  • Current Price: ₹609
  • Stock P/E: 64.5
  • ROE: 10.8%
  • ROCE: 14.2%
  • Book Value: ₹129
  • Dividend Yield: 0.00%
  • 52W High / Low: ₹759/381

In Sep 2026, SHREE GANESH REMEDIES LTD (SGRL) reported sales ₹23.29 Cr and net profit ₹1.63 Cr.

Annual TTM: sales ₹92 Cr, net profit ₹12 Cr.

Shareholding: Promoters 72.83% (Sep 2026), FIIs 0.00% (Sep 2026), DIIs 0.99% (Sep 2026), Public 26.17% (Sep 2026), No. of Shareholders 8,234% (Sep 2026).

SGRL quarterly results (₹ Cr.)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales27.0524.4324.6730.3221.1133.2014.3623.29
YoY Sales growth-3.29%-34.56%-0.44%-6.22%-21.96%+35.90%-41.79%-23.19%
Expenses17.1414.5517.3720.7014.3821.8211.0119.35
Operating Profit9.919.887.309.626.7311.383.353.94
OPM %36.64%40.44%29.59%31.73%31.88%34.28%23.33%16.92%
Other Income0.712.290.660.690.661.020.941.41
Interest0.380.960.941.010.740.880.320.58
Depreciation2.702.422.422.592.672.802.442.50
Profit before tax7.548.794.606.713.988.721.532.27
Tax %27.85%24.80%25.00%26.23%22.36%28.10%27.45%27.75%
Net Profit5.436.603.454.963.106.271.121.63
EPS in Rs4.235.142.693.862.414.880.871.27
Raw PDF————————
SGRL profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5849719112610910992
Sales growth+66%-16%+45%+28%+38%-14%+1%-14%
Expenses4735536884697467
Operating Profit1114182342393525
OPM %19%28%25%26%33%36%32%28%
Other Income42413434
Interest00001243
Depreciation23346101010
Profit before tax1313182038312416
Tax %24%25%26%25%26%26%26%—
Net Profit1010131528231812
EPS in Rs8.028.0611.0712.5523.2418.0013.849.43
Dividend Payout %14%18%4%2%2%0%0%—
SGRL balance sheet (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital910121313131313
Reserves33405075109132150153
Borrowings2003336383126
Other Liabilities81015181281418
Total Liabilities526177138171192208210
Fixed Assets161927588195105102
CWIP023151791316
Investments73005181312
Other Assets2937476469707881
Total Assets526177138171192208210
SGRL cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-5431317303124
Cash from Investing Activity-0-3-1-12-51-33-35-9
Cash from Financing Activity-0-0-1-13910-1-12
Net Cash Flow-512057-63
Free Cash Flow-543-2-32-177
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit-60%35%24%75%73%92%104%81%
SGRL shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters72.80%72.80%72.80%72.80%72.80%72.83%72.83%72.83%
FIIs0.01%0.01%0.01%0.01%0.00%0.00%0.00%0.00%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.52%0.99%
Public27.19%27.20%27.20%27.19%27.20%27.16%26.65%26.17%
No. of Shareholders8,6958,9789,1668,7528,4428,0587,8228,234
SGRL key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10110499941125975109
Inventory Days12556206132138156223209
Days Payable753910192118516182
Cash Conversion Cycle151120205134133164238236
Working Capital Days14510215813312289111128
ROCE %27%33%28%33%22%28%19%14%
SGRLUpdated 10 Nov 2026, 16:03

Shree Ganesh Remedies Ltd

Market Cap

₹781Cr.

Current Price

₹609

High / Low

₹759/381

Stock P/E

64.5

ROE10.8%
ROCE14.2%
Book Value₹129
Face Value₹10.0
Dividend Yield0.00%

About

Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.[1][2]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Sep 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days931331367810110499941125975109
Inventory Days13213010310212556206132138156223209
Days Payable43329043753910192118516182
Cash Conversion Cycle183232149137151120205134133164238236
Working Capital Days16020217212814510215813312289111128
ROCE %16%12%26%27%27%33%28%33%22%28%19%14%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SHREE GANESH REMEDIES LTD (SGRL)?

The reported market capitalisation for SHREE GANESH REMEDIES LTD (SGRL) is ₹781Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SGRL?

The current price shown for SHREE GANESH REMEDIES LTD (SGRL) on Fincrux is ₹609 with a 52-week high/low of ₹759/381.

What is the P/E ratio of SHREE GANESH REMEDIES LTD (SGRL)?

The stock P/E for SHREE GANESH REMEDIES LTD (SGRL) is 64.5 on Fincrux, with ROE at 10.8% and ROCE at 14.2%.

What were SGRL latest quarterly results?

For Sep 2026, SHREE GANESH REMEDIES LTD (SGRL) reported sales ₹23.29 Cr and net profit ₹1.63 Cr (figures in ₹ crore unless noted).

What are SGRL annual sales and net profit?

For TTM, SHREE GANESH REMEDIES LTD (SGRL) shows sales of ₹92 Cr and net profit of ₹12 Cr on the Fincrux profit & loss statement.

Who owns SHREE GANESH REMEDIES LTD (SGRL)?

Latest shareholding for SHREE GANESH REMEDIES LTD (SGRL) on Fincrux: Promoters 72.83% (Sep 2026), FIIs 0.00% (Sep 2026), DIIs 0.99% (Sep 2026), Public 26.17% (Sep 2026), No. of Shareholders 8,234% (Sep 2026).

Where can I find SHREE GANESH REMEDIES LTD (SGRL) financials?

SHREE GANESH REMEDIES LTD (SGRL) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SGRL balance sheet and cash flow?

Yes. The SHREE GANESH REMEDIES LTD (SGRL) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.